Clinical Trial Update: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) [Phase 3]

View source ↗

Summary

Phase 3 trial MAGNITUDE evaluating NTLA-2001 in transthyretin amyloidosis with cardiomyopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Cardiomyopathy

Drugs mentioned

• NTLA-2001

Snippet

Sponsor: Intellia Therapeutics | Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Status: RECRUITING